Core Viewpoint - Samsung Medical emphasizes the importance of market value management, integrating it into daily operations and strategic development to enhance operational efficiency and competitiveness [2] Group 1: Market Value Management - The company is committed to continuous improvement in operational efficiency and competitiveness as part of its market value management strategy [2] - Samsung Medical acknowledges that stock price fluctuations are influenced by various complex factors, including macroeconomic conditions, industry trends, and market dynamics [2] Group 2: Future Strategies - The company plans to implement comprehensive measures such as strategic leadership, operational optimization, improved corporate governance, enhanced shareholder returns, and increased investor interaction to boost both intrinsic and market value [2] - In the event of any changes to the company's stock name, it will adhere strictly to relevant laws, regulations, and corporate bylaws regarding timely information disclosure [2]

Core Viewpoint - Yongtai Energy (600157) emphasizes the importance of long-term and continuous market value management, acknowledging that stock prices may not always reflect the company's true value due to various market factors [1] Group 1: Market Value Management - The company recognizes that stock prices may not fully represent its true value due to differences in industry conditions, sector trends, and investor preferences [1] - Yongtai Energy has taken measures such as increasing core management personnel's shareholdings, stock buybacks, and cash dividends to maintain its stock price [1] - The company is implementing a share buyback plan of 300 million to 500 million yuan to stabilize its stock price and promote a return to a reasonable level [1] Group 2: Business Strategy - The company is committed to continuously enhancing its coal and electricity main business and accelerating the construction of key projects at the Haizetan coal mine [1] - Yongtai Energy aims to improve its operational performance and long-term investment value through these strategic initiatives [1]

Group 1 - The company believes that its value will grow alongside its performance [1] - The company has established a market value management system to enhance communication with the secondary market [1] - The company aims to actively disseminate its value to ensure investors have timely and in-depth understanding of its business and highlights [1]

（编辑 丛可心） 证券日报网讯 1月22日，天山股份在互动平台回答投资者提问时表示，股票价格受宏观经济环境、行业 周期波动、资本市场供给和投资者风险偏好等多方面因素影响。公司管理层始终关注公司股价表现，高 度重视市值管理工作，并于2025年制定并披露了《估值提升计划》，从经营提升、规范治理、ESG管 理、投资者回报、强化投资者关系管理、长效机制等维度，提出了具体实施方案（详细内容请见公 告）。 ...

Core Viewpoint - The company emphasizes the importance of market value management and compliance with relevant regulations to enhance shareholder value and protect shareholder rights [1] Group 1 - The management team is committed to market value management and adheres to the "Listed Company Information Disclosure Management Measures" and "Guidance No. 10 on Market Value Management" [1] - The company plans to focus on its core business and strengthen its competitive advantages [1] - Strategies include enhancing investor returns, optimizing information disclosure, and improving investor relations [1]

Core Viewpoint - Kangguan Technology (001308) emphasizes the importance of market value management and investor relations, showcasing management's confidence in the company's future development and long-term investment value through a series of share buybacks since its listing [1]. Group 1 - The company has seen an increase in shareholding by management personnel since its listing, indicating strong confidence in the company's prospects [1]. - A series of buyback initiatives reflect the management's recognition of the company's sustainable and steady development [1]. - The management's actions demonstrate a firm belief in the long-term investment value of the company [1].

是否活成一个NPC，是否不配有姓名？ 1月20日，历史上一个平淡的日子，唯一的热闹，可能是大寒之日上海飘雪。同日，另一场寒潮却无声 无息，恒生生物科技指数（HSHKBIO）成交额跌破100亿港币，与2025年最高点相比下降近80%，15家 港股18A公司日成交额不足100万港币。 创新药在研发主战场外，正在开辟争夺流动性的第二战场。 技术和资本，一体两面，是创新药企的两大属性。早期生物科技没有自我造血功能，全靠资本输血。成 熟创新药企在每一个重要节点，跃升到更高发展阶段，也靠资本支持。 当前，通过港股18A通道上市的生物科技企业已达85家(含摘B)，还有超过80家递表排队，而流动性却 在指缝间溜走。自研能力不够硬，又不做市值管理的公司，等于自动退出流动性争夺战，被边缘化，被 遗忘，直至丧失融资能力。 每家Biotech都曾经满怀绚丽的梦想，但时间会褪色一切，会否一不注意就成为创新药背景板上没有姓 名的NPC？ FDA敌意渐浓 进入2026年，FDA连续对多项生物制品上市申请（BLA）发出Complete Response Letter（CRL），拒绝 批准或要求补充关键临床与CMC（化学、生产与控制）证据，显 ...

Core Viewpoint - The company emphasizes the importance of market value management and focuses on its core business to enhance operational quality and profitability, aiming for performance growth to reflect its intrinsic value in the market [1] Group 1: Market Value Management - The company is committed to market value management and aims to ensure that its market performance reflects its intrinsic value through continuous improvement in operational quality and profitability [1] - The company is optimizing its investor relations management to enhance communication with the capital market, ensuring timely, accurate, and transparent information disclosure [1] Group 2: Strategic Initiatives - The company is advancing a dual-driven strategy of "public engineering optimization + stock optimization," leveraging technological research and development along with industry chain collaboration to strengthen its core competitiveness [1] - Future initiatives include optimizing the dividend return mechanism to continuously protect shareholder rights and promote a virtuous cycle between company value and market performance [1]

Core Viewpoint - The company, Zhonggong International, is facing significant pressure on its stock price due to the low valuation levels in the civil engineering construction industry, which has remained at historical lows [1] Group 1: Company Performance - The company's price-to-book ratio is currently higher than the industry average, indicating potential overvaluation relative to peers [1] - In 2025, the company reported a net cash flow from operating activities of 882 million yuan, reflecting a year-on-year improvement of 207.1%, showcasing strong operational quality [1] Group 2: Risk Management and Project Execution - The company has established a comprehensive risk management and project management system over its 40 years of overseas operations, ensuring effective handling of projects [1] - Prior to project commencement, the company secures funding sources and implements measures such as enhancing project performance quality, improving receivables management, and insuring export credit to safeguard project payments [1] Group 3: Value Enhancement Strategy - The company aims to enhance the quality of its listed entity and strengthen market value management to improve investment value and shareholder returns, guiding the reasonable return of company value [1]

证券日报网讯1月22日，维业股份（300621）在互动平台回答投资者提问时表示，公司始终认为专注做 好经营管理提升公司质量是最有效的市值管理手段，公司将持续增强经营管理能力，努力实现更好的业 绩以回报股东。 ...